Skip to main content
Premium Trial:

Request an Annual Quote

HealthLinx Says Sigma-Aldrich Patent Challenge Is Rejected

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian biomarker discovery firm HealthLinx said this week that the European Patent Office has rejected Sigma-Aldrich's objection to a patent issued to HealthLinx covering IgY immunodepletion technology.

The patent at the center of the dispute, EP1540304, is entitled, "Depletion of Plasma Proteins," and covers technology that is used in discovering protein biomarkers.

According to HealthLinx, it has been defending its patent position over the past 18 months. It noted that Sigma-Aldrich has a final opportunity to argue its position in September, but the firm is "confident that no additional material arguments can be presented by Sigma that would alter the EPO's decision."

Melbourne-based HealthLinx also said that it has a patent covering the technology in Australia and has offered Sigma the opportunity to license the technology. However, Sigma chose to withdraw its products that infringe the patent from the Australia market instead, it said.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.